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a b s t r a c t
Therapeutic interventions aimedat increasinghigh-density lipoprotein (HDL) levels inorder to reduce the
residual cardiovascular (CV) risk of optimally drug treated patients have not provided convincing results,
so far. Transfer of cholesterol from extrahepatic tissues to the liver appears to be the major atheroprotec-
tive function of HDL, and an elevation of HDL levels could represent an effective strategy. Inhibition of the
cholesteryl ester transfer protein (CETP), raising HDL-cholesterol (HDL-C) and apolipoprotein A-I (apoA-
I) levels, reduces low-density lipoprotein-cholesterol (LDL-C) and apoB levels, thus offering a promising
approach. Despite the beneﬁcial inﬂuence on cholesterolmetabolism, off-target effects and lack of reduc-
tion in CV events and mortality (with torcetrapib, dalcetrapib and evacetrapib) highlighted the complex
mechanism of CETP inhibition. After the failure of the above mentioned inhibitors in phase III clinical
development, possibly due to the short duration of the trials masking beneﬁt, the secondary preven-
tion REVEAL trial has recently shown that the inhibitor anacetrapib signiﬁcantly raised HDL-C (+104%),
reduced LDL-C (−18%), with a protective effect on major coronary events (RR, 0.91; 95%CI, 0.85–0.97;
p=0.004). Whether LDL-C lowering fully accounts for the CV beneﬁt or if HDL-C-rise is a crucial factor
still needs to be determined, although the reduction of non-HDL (−18%) and Lp(a) (−25%), should be also
taken into account. In spite of the positive results of the REVEAL Study, Merck decided not to proceed in
asking regulatory approval for anacetrapib. Dalcetrapib (Dal-GenE study) and CKD-519 remain the two
molecules within this area still in clinical development.
© 2017 Elsevier Ltd. All rights reserved.
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1. Introduction: the CETP inhibitors, aim of therapeutics39
and individual agents40
Elevated low-density lipoprotein cholesterol (LDL-C) is the41
major risk factor for the development of cardiovascular disease42
(CVD) and treatment with statins has achieved considerable suc-43
cess in patients with dyslipidaemia and CVD [1]. However, a44
signiﬁcant number of patients remains at increased risk, not45
because of LDL-C elevation, but due to other lipid abnormalities,46
such as low high- density lipoprotein (HDL) cholesterol [2]. Epi-47
demiological and clinical studies link low levels of HDL with an48
increased risk of atherosclerotic CVD [3], although a direct causal49
role for HDL in CVD remains controversial [4,5]. Indeed, therapeu-50
tic interventions aimed at increasing HDL levels in order to reduce51
the residual CV risk of optimally drug treated patients have not52
provided convincing results, so far [6–9]. Among these therapeu-53
tic strategies, the inhibition of cholesteryl ester transfer protein54
(CETP) has provided the best results, with dose-dependent HDL-C55
elevations 100% or more [10].Q456
The earliest evidence on the possible role of CETP in regulating57
HDL-C levels came from genetic studies in Japan, on communi-58
tieswheremany individuals showed dramatic elevations of HDL-C.59
Remarkably, however, the very highHDL-C levels, initially believed60
to be associated with a reduced incidence of coronary heart dis-61
ease (CHD), were instead linked to a paradoxically enhanced CV62
risk [11]. The crucial role of CETP mutations, with a loss of activity,63
became clear after the identiﬁcation of this transfer protein. CETP64
is, indeed, a hydrophobic glycoprotein with a molecular weight of65
74kDa [12] responsible for a net transfer of cholesteryl esters (CE)66
from HDL to VLDL, IDL and LDL in exchange for triglycerides (TG);67
it also mediates the reciprocal transfer of TGs from LDL, VLDL to68
HDL. When VLDL levels are normal, then the transfer from HDL to69
LDL prevails. Conversely, when VLDL levels are raised, eg in type70
2 diabetes, CE transfer is primarily from HDL to large VLDL parti-71
cles which become CE enriched and potentially more atherogenic72
[13]. The end result of the process is a TG-enriched HDL leading73
to the catabolism of TGs in the newly formed HDL. The result-74
ing “small, CE-poor HDL” appears to have an enhanced cholesterol75
efﬂux capacity [14] and, according tomanyauthors,maybe respon-76
sible for the arterial protection [15]. This process ismediated by the77
ATPbindingcassette (ABC) transporters:ABCA1exports cholesterol78
mainly to poorly-lipidated apo A-I (small pre-1-HDL) or to lipid-79
free A-I; conversely, the ABCG1 transporter mediates cholesterol80
efﬂux to mature HDL [16].81
Thepharmacological inhibitionof CETPhas beenpursued for the82
last 20 years or so and showed beneﬁcial inﬂuence on cholesterol83
metabolism (ie, raised HDL-C and lowered LDL-C and apolipopro-84
tein B (apo B) levels). Nevertheless, when the ﬁrst three CETP85
inhibitors (torcetrapib, dalcetrapib and evacetrapib) were added to86
the background statin therapy, they either paradoxically increased87
the risk of CV disease and death (in the case of torcetrapib) or had88
neutral outcomes (dalcetrapib and evacetrapib) [17]. Further, off-89
target adverse effects were seen, in particular raised aldosterone90
and blood pressure (BP). Conversely, a new CETP inhibitor, anace-91
trapib, reduced CV events with modest off-target events [18].92
2. Mechanism of action of CETP inhibitors93
CETP is ahydrophobic glycoprotein,mainly secretedby the liver.94
Often bound to HDL in the circulation, it facilitates either homoex-95
change, ie the bidirectional transfer of the same neutral lipid, or96
heteroexchange, ie the net mass transfer of CE and TGs between97
lipoproteins [13,19]. CETP is a banana-shaped asymmetric pro-98
tein forming a bridge between HDL, LDL and/or VLDL, with the99
N-terminal-barrel domainpenetrating theHDL surface and theC-100
terminal -barrel domain penetrating the lipoprotein surface [20, 101
21]. The C-terminal domain of CETP may thus interact with HDL 102
and LDL or VLDL, thus building a ternary complex leading to a con- 103
formational change, resulting in a hydrophobic tunnel whereby CE 104
is transferred from HDL to lower density lipoproteins [22]. More 105
recent ﬁndings, however, indicate that the ternary tunnel complex, 106
ie HDL-CETP-LDL, is not a prerequisite for the transfer, since anti- 107
bodies against different CETP epitopes do not interfere with the 108
transfer of CE [23]. 109
CETP inhibitors were thus designed with the aim of block- 110
ing or of interfering with the activity of CETP. Depending on 111
their chemical structure, CETP inhibitors that have reached late 112
stage clinical development are categorized into CETP inhibitors 113
(torcetrapib, anacetrapib and evacetrapib) and modulators (dal- 114
cetrapib). As shown in Fig. 1, torcetrapib is representative of 115
the tetrahydroquinoline series of inhibitors; it is a 3,5-bis- 116
triﬂuoromethyl-benzene derivate. Anacetrapib contains the triad 117
of triﬂuoromethyl groups found in torcetrapibwith a distinct biaryl 118
moiety. Evacetrapib contains ahomologated coreof torcetrapib and 119
the 3,5-bis-triﬂuoromethyl-benzyl group with a methyl tetrazole 120
and cyclohexane carboxylic acid side chain. Conversely, dalcetrapib 121
belongs to the chemical class of benzenethiols containing an ortho- 122
thio-anilide core [24]. 123
Biochemical characterization of CETP inhibitors indicates that 124
anacetrapib, torcetrapibandevacetrapibpotentlyblockCETPmedi- 125
ated CE-TG transfer activity, whereas dalcetrapib is a weaker 126
inhibitor, displaying a time-dependent inhibition of CETP neutral 127
lipid transfer activity [25]. Anacetrapib and torcetrapib bind CETP 128
in a reversiblemanner,whereas, dalcetrapib does it covalently; this 129
compound inhibits neutral lipid transfer by a disulﬁde bond forma- 130
tion with the cysteine 13 of CETP, thus leading to a conformational 131
change in CETP [26]. These features characterizing homotransfer vs 132
heterotransfer can have a direct impact on pre- HDL formation. 133
Indeed, CETP facilitates the remodeling of plasma HDL particles 134
by favoring the interconversion of apoA-I-containing alpha-HDL 135
to small, lipid-poor, pre--HDL [27] and by facilitating CE transfer 136
among HDL subfractions [28]. 137
Overall, the in vitro studies have conﬁrmed that torcetrapib 138
and anacetrapib can be classiﬁed as CETP inhibitors, whereas dal- 139
cetrapib, a CETP modulator, inhibits only the heterotypic (HDL to 140
LDL/VLDL) transfer of CE/TG preserving pre--HDL formation. Rel- 141
ative to evacetrapib, eterotypic and homotypic CE transfer has not 142
been fully elucidated [29, 30]. 143
These particles are responsible for the ATP binding cassette 144
subfamily A member 1 (ABCA1)-mediated cholesterol efﬂux and 145
initiation of RCT [28]. Conversely, CETP inhibitors, by reducing 146
both the heterotypic and HDL-to-HDL homotypic (HDL3 to HDL2) 147
lipid transfers impede the pre--HDL formation [25,31] (Fig. 2). 148
These differences in the mode of action can possibly explain the 149
unchanged neutral fecal sterol formation in the case of the torce- 150
trapib and anacetrapib, whereas dalcetrapib apparently increases 151
the neutral sterol loss [31]. The only exception, evacetrapib, 152
increased not only total cholesterol efﬂux capacity but also ABCA1- 153
speciﬁc cholesterol efﬂux capacity and pre--HDL formation [32]. 154
Somewhat at odds, the in vivo studies have shown that 155
anacetrapib promotes pre--HDL functionality with no effects on 156
cholesterol absorption [33]. An increased efﬂux from the basolat- 157
eral side of the intestinal wall through ABCA1 to pre--HDL in 158
fact occurs, potentially leading to a facilitated fecal cholesterol 159
excretion. Anacetrapib treatment does not, however, impair the 160
CE ﬂux into the larger HDL2 particles [34]. Of note, depending on 161
the species considered (rabbits vs monkeys), anacetrapib and dal- 162
cetrapib have a different impact on HDL structure and function 163
[35]. 164
Finally, controversies in the remodeling of HDL particles upon 165
CETP inhibition should be also considered. Carriers of CETP muta- 166
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Fig. 1. Chemical structure of torcetrapib, anacetrapib, evacetrapib and dalcetrapib.
Fig. 2. Proposed effects of dalcetrapib and torcetrapib onneutral lipid transfers amonghigh-density lipoprotein (HDL) subparticles. Panel A). Cholesteryl ester transfer protein
(CETP) transfers neutral lipids (cholesteryl ester (CE) and triglycerides (TGs)) among HDL and HDL subparticles and changes conformation to accommodate low-density
lipoprotein (LDL) and very low-density lipoprotein (VLDL). Panel B). Dalcetrapib prevents the change in conformation required for transfer activity, leaving unaffected CETP-
mediated exchange among HDL subparticles. Panel C). Torcetrapib increases binding afﬁnity of CETP for lipoproteins, decreasing CE and TG exchange between lipoproteins,
including the one among HDL subparticles. Reproduced with permission [31].
tions show remarkable changes in the concentration, composition,167
turnover and function of both HDL and LDL. The very large HDL in168
these patients are TG-poor, but enriched with CE, apo A-I, apo A-II,169
apo C-III and apo E [36]; apo E enrichment may lead to a higher170
afﬁnity for the LDL-receptor. The increased HDL-C is mainly conse-171
quent toan incrementofHDL2-C,whereasHDL3-C levels arenormal172
or low [37]. HDL from CETP deﬁcient patients appear to promote173
cholesterol-efﬂux from foamcells in anABCG1-dependentmanner,174
possibly due to an increment in LCAT and apo E content [37]. Addi-175
tion of CETP to serum from deﬁcient patients transforms large HDL176
to smaller very-high density lipoproteins with a potent cholesterol 177
efﬂuxing capacity [38]. 178
In the context of the ongoing debate on the protective role of 179
HDL, it should be noted that the HDL particle number rather than 180
HDL-C concentrations per se, may be of greater importance in the 181
prediction of CV risk: torcetrapib raised HDL particle number by 182
only 1% despite a 53% increase in HDL-C [39,40] and dalcetrapib 183
raised HDL particles by 9.3% despite a 29.1% increase in HDL-C 184
[41]. Further, besides CETP, major enzymes and transporters are 185
also involved in changes in HDL particle size, lipid and protein 186
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Table 1
Pharmacokinetic characteristics of CETP inhibitors.
Torcetrapib Dalcetrapib Evacetrapib Anacetrapib
Bioavailability 33–45% NA 45% 4% (fasted) 26% (low fat) 49% (high
fat)
Effect of food Exposure is higher in fed than
fasted state
2-fold increase (low-fat) or
more with high-fat
44% higher with high-fat 2-, 3-fold increased (low-fat) or
6–8 fold (high-fat)
logP 7.35 7.92 7.03 7.95
Vd 1.1–2.5 l/kg (77–175 l) NA 548–827 l 253 l
Tmax 6.3h 3.5–6h 3h 4–5h
Half-life (t1/2) Estimated 25h long (211h)
terminal half-life
18.4–20.4h 40-44h Estimated 20h long (2530h)
terminal half-life (accumulated in
adipose tissue)
Metabolism (CYP450) 3A No interaction with 3A4
inhibitors. Hydrolysis,
glucuronidation, oxidation
and methylations
3A4 3A4
Renal clearance 63% NA NA <0.1%
Hepatic clearance 12.7% NA NA 87%
References [48] [52,58,141,142] [43,44,54,55] [46,51,53,59]
NA: not available.
composition, particularly in hypetriglyceridemic conditions: the187
lecithin-cholesterol acyltransferase (esterifying cholesterol), hep-188
atic or lipoprotein lipases (hydrolyzing TGs) and the phospholipid189
transfer protein [42].190
3. Pharmacokinetics and pharmacodynamics191
The main pharmacokinetic parameters of CETP inhibitors are192
summarized in Table 1. The oral absorption of all CETP inhibitors193
is rapid with Tmax values of 3h for evacetrapib [43,44], 4–5h for194
anacetrapib [45, 46], 3.5–6h for dalcetrapib [47] and 6.3h for torce-195
trapib [48].196
It is important tonote that dalcetrapib is a thioester prodrug that197
is hydrolysed to generate a pharmacologically active thiol. Hydrol-198
ysis is rapid in lipase-containing gastrointestinal ﬂuids [49,50], so199
that the thioester is not systemically available and the thiol appears200
to be the principal species absorbed from the gastrointestinal tract.201
The bioavailability of anacetrapib is signiﬁcantly inﬂuenced by202
the feeding status, with only 4% absorption under fasting condi-203
tion, 26% after low fat meal and 49% with high fat meal [45,51].204
Similar ﬁndings, although at lower extent, have beenobservedwith205
torcetrapib [48], dalcetrapib [52], andevacetrapib [44].Anacetrapib206
is characterized by poor water solubility (LogP ≈7) and modest207
permeability, hence, it is likely that the reason for poor bioavail-208
ability is largely a function of poor absorption rather than other209
factors, including ﬁrst-pass metabolism. The lipophilic character-210
istics of CETP inhibitors, all characterized by high logP value, induce211
their accumulation in peripheral tissues, ie the adipose tissue, thus212
showing high volume of distribution (Table 1) [51]. For instance,213
it has been calculated that anacetrapib has a volume of periph-214
eral compartment of 253 l [53], while evacetrapib shows a volume215
of distribution during the terminal phase following oral dose of216
548–827L [54,55]. All agents have a prolonged half-life, maximal217
for anacetrapib that shows a 2530h terminal half-life, due to accu-218
mulation in adipose tissue [51] (Table 1).219
Interestingly, in a subset of patients from the DEFINE study, it220
was found that modest elevations in HDL-C and low anacetrapib221
concentrations were still detectable 2–4 years after the last dosing222
[56]. Preclinical and clinical experiments with extended recovery223
phases were then speciﬁcally designed to assess whether there224
was a deep tissue reservoir that may be contributing to persistent225
plasma exposure to anacetrapib after cessation of treatment [51].226
In particular, it appears that the brown adipose tissue may be a227
temporary reservoir for the drug in the short term whereas white228
adipose is likely to be a major long-term reservoir [51,57].229
All agents seem to have a mean route of elimination 230
by hepatic metabolism mainly by CYP3A4/5 and, in case of 231
dalcetrapib, by hydrolysis, glucuronidation, oxidation and methy- 232
lations (Table 1). Both hepatic and renal impairment altered 233
dalcetrapib pharmacokinetics and increased its exposure [58]. Dif- 234
ferently, pharmacokinetic studies conductedwithanacetrapibhave 235
shown that the majority of the radioactive dose is recovered as 236
unchanged parent drug in the feces [59]. Anacetrapib is negligibly 237
excreted in theurinewith<0.1%of the radioactivedose recoveredas 238
unchanged parent. For this reason, also severe renal insufﬁciency 239
does not signiﬁcantly affect anacetrapib pharmacokinetic proﬁle 240
[60]. 241
Since anacetrapib is primarily metabolized by cytochrome 242
CYP3A, its pharmacokinetic proﬁle is inﬂuenced by strong 243
inhibitors and inducers of CYP3A [61–63]. Anacetrapib expo- 244
sure is not impacted by age, weight, sex, and moderate hepatic 245
impairment [60,63]. Finally, no meaningful differences have been 246
observed between Japanese and white subjects with respect to 247
pharmacokinetic parameters after single oral doses of anacetrapib 248
[46]. 249
Considering the pharmacodynamic proﬁle of the different CETP 250
inhibitors, torcetrapib inhibits CETP by forming a complex between 251
CETP and HDL, thus, leading to a high signiﬁcant HDL rise in 252
humans (+60%) with a concomitant LDL-C reduction of approx- 253
imately 20%. Torcetrapib inhibits CE transfer with high potency 254
(IC50 =13±2.7nM) but the ILLUMINATE (Investigation of Lipid 255
Level Management to Understand Its Impact in Atherosclerotic 256
Events) trial was prematurely ended due to an increased morbid- 257
ity and mortality in the active treatment group compared with 258
the placebo group [64]. After the termination of this and other 259
negative trials (RADIANCE 1 and ILLUSTRATE), it was found that 260
treatment with torcetrapib raises systolic blood pressure (SBP), 261
although rather inconstantly in the different studies [65]. Aldos- 262
terone, sodium and bicarbonate levels were also raised while 263
potassium decreased [66]. 264
The speciﬁc off-target effects of torcetrapib do not clarify the 265
increased incidence of cardiovascular (CV) events. Indeed, in the 266
four studieswith torcetrapib (ILLUMINATE, ILLUSTRATE,RADIANCE 267
1 and RADIANCE 2) the calculated event rate, before and after 268
torcetrapib, was estimated as 28.4% (10-y risk) by using the classi- 269
cal Framingham risk score. Conversely, treatment with torcetrapib 270
plus atorvastatin, leading to a total cholesterol of 200 and HDL-C of 271
50mg/dl should reduce the risk estimate to 14.3%. The lack of this 272
beneﬁt is not explained by a rise of blood pressure to 140mmHg, 273
extreme for a patient treated with this combination: this should 274
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raise the risk score to just16.3%, ie certainly far fromtheassumption275
that it could fully cancel the risk beneﬁt of torcetrapib [67].276
The following CETP inhibitors, developed with the objective277
of obtaining drugs with no off-target effects, led to the iden-278
tiﬁcation of dalcetrapib, evacetrapib and anacetrapib. Whereas279
dalcetrapib has a 90 foldweaker potency (IC50 =1.170±443nM) vs280
torcetrapib (IC50 =13±2.7nM), anacetrapib has a similar potency281
(IC50 =17±4.8nM) [68,69]. The in vitro activity of evacetrapib282
shows a more potent activity based on IC50 values, (ie, 5.5nM),283
thus making evacetrapib the most potent among available CETP284
inhibitors (Table 1) [68].285
Theeffectof anacetrapibonatherosclerosishasbeenextensively286
investigated in animal models, including the APOE*3Leiden.CETP287
mice [70], rabbits [35], andmonkeys [35]. The atheroprotective [70]288
effect and positive lipid proﬁlemodiﬁcations [35] were in linewith289
the evidence that, in mouse atherosclerosis models, CETP expres-290
sion aggravates atherosclerosis development [71,72].291
Discordant results have, however, been observed with differ-292
ent CETP inhibitors (dalcetrapib, evacetrapib and anacetrapib) on293
experimental atherosclerosis [35,73]. While in rabbits both dal-294
cetrapib and anacetrapib increased HDL-C, in monkeys dalcetrapib295
had the opposite effects, with an increase of LDL-C and a reduc-296
tion of HDL-C [35], indicating that the impact on HDL metabolism297
can vary according to the metabolic environment [35]. Torcetrapib298
also failed to enhance the antiatherogenic effects of atorvastatin299
and induced a pro-inﬂammatory, vulnerable plaque phenotype in300
APOE*3Leiden.CETPmice [74]. Finally, different effects on endothe-301
lial function were displayed by evacetrapib and anacetrapib in the302
APOE*3Leiden.CETPmice [73]. Thus,most but not all studies in rab-303
bits and mice have shown a favorable effect of CETP inhibition on304
atherosclerosis development [73–75].305
The off-target effects of these molecules, in particular of torce-306
trapib, may be possibly responsible for their failures in phase307
III clinical development [64]. Interestingly, off-target effects have308
been also observed in experimental settings for both anacetrapib309
and dalcetrapib [76]. The two inhibitors reduced the mature form310
of sterol-regulatory element binding protein 2 (SREBP2), leading to311
a lower transcription of the liver LDL receptor (LDLR) andof propro-312
tein convertase subtilisin kexin type 9 (PCSK9) [76]. The negative313
regulation of the SREBP pathway by anacetrapib manifested also in314
mice, with absent CETP activity, with a consequent rise of choles-315
terolemia [76. Similar results were observed in the APOE*3Leiden316
mice, also n]ot expressing CETP, where anacetrapib decreased both317
plasma levels of PCSK9and cholesterolemia [77]. Aprotective effect318
of anacetrapib on vascular restenosis has been observed in theNew319
Zealand White rabbits [78], leading to the intriguing hypothesis320
that anacetrapib could inhibit smoothmuscle cell proliferation and321
migration by reducing PCSK9 expression [79].322
In conclusion, CETP inhibitors that have undergone clini-323
cal development show strikingly different pharmacokinetic and324
pharmacodynamic proﬁles as well as peculiar pharmacological325
activities that go beyond the inhibition of CETP. In particular,326
whereas the effect on CETP is completely inhibited by torcetrapib,327
anacetrapibandevacetrapib, dalcetrapibexerts amodulatoryactiv-328
ity. In terms of the HDL-C rise, evacetrapib and anacetrapib are the329
most potent, followed by dalcetrapib, whereas LDL-C reduction is330
in a similar range for torcetrapib, evacetrapib and anacetrapib,with331
minimal effects of dalcetrapib (Table 2).332
4. Clinical studies on CETP inhibitors333
Ten randomized controlled trials on CETP inhibitors, ie334
torcetrapib, dalcetrapib, evacetrapib and anacetrapib have been335
completed (Table 2), enrolling a total of 78,602 patients, the largest336
being the last, ie the REVEAL Study, enrolling 30,449 individu-337
als in Europe, North America and China. All randomizations were 338
between the addition of all CETP inhibitors and placebo with all 339
patients receiving statin treatment. Duration of follow up ranged 340
from 8 to 48 months. 341
4.1. Anacetrapib 342
The dose-dependent effects of anacetrapib on the lipoprotein 343
proﬁle have been ﬁrst evaluated in a multi-center phase II ran- 344
domized controlled trial, after the administration of 10, 40, 150 and 345
300mg daily for 8 weeks, in the presence or absence of 20mg ator- 346
vastatin [80]. Similar to evacetrapib, anacetrapib exertedamaximal 347
reduction of LDL-C, ie of about 40%, and of 70% in combination 348
with atorvastatin, compared to placebo. Anacetrapib raised HDL- 349
C levels by about 130%; the effect was similar when combined to 350
atorvastatin. 351
The DEFINE phase III study was then performed by recruiting 352
1623 patients with or at high risk of coronary disease treated with 353
statins [81]. Anacetrapib 100mg lowered LDL-C by about 40% and 354
raised HDL-C by about 140%, ie similar to the phase II trial. Interest- 355
ingly, in this study, Lp(a)was reduced of about 40%. The lipoprotein 356
proﬁle was maintained in patients who continued treatment for 357
two years. Regarding safety, evaluated after 76 weeks of treat- 358
ment, anacetrapib did not lead to signiﬁcant differences in BP, 359
electrolytes, CPK elevations, ormuscle symptoms. However, signif- 360
icantly, more patients in the placebo group experienced ALT/AST 361
elevations (0.1% vs 1.0%; p=0.02). In terms of coronary revascu- 362
larization, anacetrapib showed a positive effect after 76 weeks: 8 363
patients (1%) on anacetrapib vs 28 patients (3.5%) on placebo. This 364
effect was lost at the 2-year follow-up: 13 patients (3.5%) anace- 365
trapib vs 13 patients (3%) placebo were revascularized. 366
Anacetrapib was then tested in patients with heterozygous 367
familial hypercholesterolaemia (FH). The REALIZE trial, a 52-week, 368
randomized, placebo-controlled study was conducted in patients 369
under optimal lipid-lowering therapy for at least 6 weeks at base- 370
line, and then randomized to either placebo or anacetrapib 100mg 371
[82]. The baseline LDL-cholesterol concentration was 2.59mmol/L 372
or higher, 1.81mmol/L or higher in patients with CV disease. 373
Change of LDL-C was the primary efﬁcacy endpoint. Anacetrapib 374
lowered the mean LDL-C by 39.7%, compared to placebo. Further- 375
more, HDL-C increased by 102.1%, and Lp(a) decreased by 31.8% in 376
anacetrapib-treated patients. 377
CV outcomes as a primary efﬁcacy endpoint have been ﬁnally 378
examined in the REVEAL study, in which 30,449 patients with 379
established CV disease were enrolled [83]. Patients were on inten- 380
sive atorvastatin regimen (ie, LDL-C≤77mg/dL) and started from 381
a very well controlled lipid proﬁle (mean LDL-C 61mg/dL; mean 382
non-HDL-C 92mg/dL and mean HDL-C 40mg/dL) [18]. Patients 383
had a mean age of 67 years; 88% had a history of CHD, 22% of 384
cerebrovascular disease, and 8% of peripheral-artery disease. Dur- 385
ing the 4.1-year follow-up, 2277 (7.5%) patients died. Anacetrapib 386
treatment raised HDL-C by 43mg/dL (+104%) and non-HDL-C was 387
reduced by 17mg/dL (−18%). Mean LDL-C was lowered by 17%. 388
The prespeciﬁed primary outcome was the ﬁrst major coronary 389
event, ie a composite of coronary death, MI or coronary revascu- 390
larizations. It was reduced by 9% in the anacetrapib group (1640 of 391
15,225patients [10.8%]vs.1803of15,224patients [11.8%];RR, 0.91; 392
95%CI, 0.85–0.97; p=0.004) [18]. Speciﬁc analysis of the different 393
components showed a positive effect of anacetrapib on MI (−13%; 394
RR: 0.87; 95%CI, 0.78–0.96; p=0.007), on the composite of MI or 395
coronary death (−11%; RR: 0.89; 95%CI, 0.81–0.97; p=0.008), as 396
well as on coronary revascularization procedures (-10%; RR: 0.90; 397
95%CI, 0.83–0.97; p=0.01). 398
Regarding secondary outcomes, the major atherosclerotic 399
events, ie a composite of coronary death, MI or presumed ischemic 400
stroke, were reduced by a non-signiﬁcant −7% (RR: 0.93; 95%CI, 401
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Table 2
(a) Features of CETP inhibitor, (b) lipid percentage changes and (c) blood pressure variations upon Torcetrapib, Dalcetrapib, Evacetrapib and Anacetrapib administration.
Torcetrapib Dalcetrapib Evacetrapib Anacetrapib
a) In vitro
Mechanism of action CETP inh. CETP modulator CETP inh. CETP inh.
Inhibition of CETP (IC50) 13±2.7nM 1170±443nM 5.5nM 17±4.8nM
b) Clinical trials ILLUMINATE Dal-OUTCOMES ACCELERATE REVEAL
daily dose 60mg 600mg 130mg 100mg
N. of patients 15,067 15,871 12,092 30,449
LDL-C (mg/dL) −24.9% minimal effect −31.1% −41%* or −17%**
apoB (mg/dL) NA minimal effect −15.5% −18%
HDL-C (mg/dL) +72.1% Range: +31–40% +133.2% +104%
non-HLD-C (mg/dL) NA NA NA −18%
c) Blood pressure ILLUMINATE Dal-OUTCOMES ACCELERATE REVEAL
Systolic (mmHg) $ +5.4 $ + 0.6 $ + 1.2 $ + 0.74
Diastolic (mmHg) $ +2.0 no signiﬁcant between-group differences $ + 0.4 $ + 0.28
References [64] [100] [93] [18]
For torcetrapib, dalcetrapib and evacetrapib data are expressed as changes from baseline in the treatment group. For anacetrapib, data are expressed as absolute differences
(value in the anacetrapib group minus the value in placebo group).
N., number; inh., inhibitor.
*direct method; ** beta quantiﬁcation; $signiﬁcant between-group differences; NA, not-applicable.
0.86–1.00; p=0.052). Although the effect of anacetrapib on pre-402
sumed ischemic strokewas not formally tested, the results showed403
no signiﬁcant effects (RR: 0.99; 95% CI, 0.87–1.12). A statistical404
reduction in the secondary outcome of major vascular events, ie,405
a composite of major coronary event or presumed ischemic stroke406
was instead found (-7%; RR: 0.93; 95% CI, 0.87–0.99, p =0.02).407
Interestingly, anacetrapib appeared to reduce the incidence of408
new-onset diabetes mellitus (5.3% vs. 6.0%) and it lowered mean409
glycated hemoglobin levels (-0.03%). This effect was not found in410
patients with diabetes at baseline. Anacetrapib modestly raised BP411
(systolic +0.7mm Hg; diastolic +0.3mm Hg) and, by the end of412
the trial, an estimated glomerular ﬁltration rate (GFR) of less than413
60ml/min per 1.73m2 body surface area (11.5% vs 10.6%, p =0.04)414
was noted in the anacetrapib group. However, no difference was415
observed in albuminuria. Finally, anacetrapib led tomoderate rates416
of creatine kinase elevations (10–40 times the upper limit of nor-417
mal, ULN), but it reduced rates ormore severe elevations (>40 times418
ULN). Thus, the REVEAL study in patients with atherosclerotic vas-419
cular disease, under intensive statin therapy for approximately 4420
years, showed that CETP inhibition reduced the incidence of major421
CV events by 9% vs placebo.422
Relative to the effects of anacetrapib on CV risk reduction, some423
further considerations relative to LDL-C, Lp(a) and non-HDL-C low-424
ering deserve attention. While a reduction in the concentration of425
cholesterol in LDL can be explained in terms of a block in the trans-426
fer of CEs fromHDL to LDL, this cannot explain the reduction in LDL427
particle concentrations, as reﬂected by a decrease in plasma apo428
B levels [84]. This open question may be in part overcome by the429
notion that, at least in experimental models, anacetrapib reduces430
plasma levels of PCSK9 [77], so far, one of the main regulators of431
LDL receptors [85–87].432
In the case of Lp(a), in mildly hypercholesterolemic subjects,433
with Lp(a) levels >20nmol/L, anacetrapib lowers Lp(a) by 34.1%,434
consequent to a 41% reduction in apo(a) production rate, with no435
effects on the fractional catabolic rate [88]. This effect is of a spe-436
cial interest since (i) elevated Lp(a) are robustly associated with an437
increased risk formajor CVDevents [89] and (ii) Lp(a)may promote438
expression of adhesion molecules and inﬂammatory cells [90].439
Non-HDL has been signiﬁcantly associated with an increased440
risk of mortality in coronary patients and baseline levels may be a441
predictor of long-term fatality in these patients [91]. In experimen-442
tal models, anacetrapib alone or in combination with atorvastatin443
reduced the atherosclerotic lesion area and severity and increased 444
the plaque stability index [70]. 445
4.2. Evacetrapib 446
The recently completed ACCELERATE (Assessment of Clini- 447
cal Effects of Cholesteryl Ester Transfer Protein Inhibition With 448
Evacetrapib in Patients at a High-Risk for Vascular Outcomes; 449
NCT01687998) studywasaimedat evaluatingwhether theaddition 450
of evacetrapib to standard medical therapy reduced the risk of CV 451
morbidity andmortality in patients with high-risk vascular disease 452
[92]. 12,092 patients (mean age, 64.9), only in secondary preven- 453
tion, were randomized to either evacetrapib (130mg; n=6038) or 454
matching placebo (n=6054), administered daily for up to 4 years, 455
in addition to standard medications (eg, any statin, high-intensity 456
statin, medication to treat high-blood pressure and aspirin). The 457
diagnosis of high risk vascular disease comprised at least one of the 458
following diagnostic criteria: i) history of acute coronary syndrome 459
within the previous 30–365days before randomization, ii) cere- 460
brovascular atherosclerotic disease, iii) peripheral arterial disease 461
and iv) diabetes mellitus (type 1 or type 2) with CAD. The primary 462
endpoint was time to ﬁrst occurrence of the composite endpoint 463
of CV death, MI, stroke, coronary revascularization, or hospitaliza- 464
tion for unstable angina. Evaluation of changes from baseline to 3 465
months in LDL-C andHDL-C levelswere listed among the secondary 466
end-points. 467
After 26 months, the primary composite end-point occurred 468
in 12.9% of patients in the evacetrapib and in 12.8% of those in 469
the placebo arms (HR: 1.01, 95% Cl: 0.91–1.11, p =0.91). Due to 470
the insufﬁcient efﬁcacy, the Data Safety Monitoring Board rec- 471
ommended early termination. Despite the failure of the primary 472
end-point, compared to placebo, evacetrapib showed highly sig- 473
niﬁcant effects on reducing LDL-C (−37%) and on raising HDL-C 474
(+132%). A lowering effect on TG (-6%), apoB (−12%) and Lp(a) 475
(−22%) were also found, as well as an increment in apoA-I (+49%). 476
Relative to safety, evacetrapib administration was associated to 477
minor increments of BP (11.4% vs 10.1 placebo, p =0.02) and of 478
hs-CRP (8.6%, p <0.001) [93]. 479
Notably, the ground for this large phase 3 clinical trial laid on the 480
results of theNCT01105975phase2 study reporting that, compared 481
to placebo, evacetrapib as monotherapy (30, 100 and 500mg/die) 482
or in combination to statins, increased HDL-C by up to 129% and 483
reduced LDL-C by up 36%. Moreover, as monotherapy, evacetrapib 484
Please cite this article in press as: N. Ferri, et al., Present therapeutic role of cholesteryl ester transfer protein inhibitors, Pharmacol Res
(2017), https://doi.org/10.1016/j.phrs.2017.12.028
ARTICLE IN PRESSG ModelYPHRS37791–13
N. Ferri et al. / Pharmacological Research xxx (2017) xxx–xxx 7
reduced in a dose-dependent fashion non-HDL-C, apoB and TG. hs-485
CRP levels were raised by up to 1.2mg/dl [94].486
A meta-analysis of 14 randomized treatment arms over a mean487
of 2 months treatment, reported that evacetrapib raised HDL-C488
(+86%, 95% CI: +67.6, +104.4, p <0.001) and reduced LDL-C (−21%,489
95%CI:−24.9,−17.3, p <0.001).No signiﬁcant effects of evacetrapib490
were found on plasma TG (−3.0%, 95% CI: −8.6, +2.7, p =0.303) [95].491
The evacetrapib program cessation led to the premature end-492
ing of other phase 3 studies, namely, (i) NCT02260635, evaluating493
the efﬁcacy and safety of evacetrapib in Japanese participants494
with primary hypercholesterolemia, (ii) NCT02260648, evaluating495
efﬁcacy and safety of evacetrapib when administered in combina-496
tion with atorvastatin for 12 weeks in Japanese participants with497
primary hypercholesterolemia and (iii) ACCENTUATE (The Addi-498
tion of Evacetrapib to Atorvastatin Compared to Placebo, High499
Intensity Atorvastatin, and Atorvastatin With Ezetimibe to Eval-500
uate LDL-C Lowering in Patients With Primary Hyperlipidemia;501
NCT02227784), a study aimed at evaluating whether evacetrapib502
can be effective in treating participants with high cholesterol503
and ASCVD and/or diabetes. Data on this latter trial gave possi-504
ble insights on the lack of clinical beneﬁt observed in the above505
described ACCELERATE trial.506
4.3. Dalcetrapib507
Dalcetrapib has been the second CETP inhibitor tested in clinical508
trials. Efﬁcacy was evaluated in the dal-HEART program composed509
of ﬁve major studies, namely, dal-PLAQUE [96], dal-VESSEL [97],510
dal-PLAQUE2 [98], dal-ACUTE [99] and dal-OUTCOMES [100]. This511
last was terminated prematurely after 31 months due to futil-512
ity, thus leading Hoffmann-La Roche to discontinue the entire513
dalcetrapib development. However, as discussed later, the era of514
genome-wide association study has led to the launch of the Dal-515
GenE study, an RCT with a design similar to the Dal-OUTCOMES,516
except for the eligibility of patients.517
Enrolling 15,871 patients and designed to evaluate the efﬁcacy518
of dalcetrapib vsplaceboonCVmortality andmorbidity in clinically519
stable patients with recent acute coronary syndromes, the dal-520
OUTCOMES trial (NCT00658515) did not showsigniﬁcant effects on521
anyprimaryend-point (HR:1.04, 95%Cl: 0.93–1.16, p =0.52).Over a522
follow-up of 31months, the administration of dalcetrapib (600mg)523
led to an increment of HDL-C by up to 40% with no impact on LDL-524
C. hs-CRP levels were 0.2mg/L higher than in placebo group (+18%525
after three months of randomization), as was SBP (+0.6mmHg;526
p<0.001). Of note, diarrhea and insomniaweremore frequentwith527
dalcetrapib. Therewere no signiﬁcant differences in diastolic blood528
pressure, pulse rate, levels of plasma aldosterone, potassium, or529
bicarbonate [100].530
By using magnetic resonance imaging (MRI) and531
18Fluorodeoxyglucose (18FDG) PET/CET, the dal-PLAQUE study532
(NCT00655473), involving 130 patients with or at high risk of CHD,533
evaluated structural and inﬂammatory changes of atherosclerotic534
plaques after dalcetrapib (600mg) vs placebo. Major ﬁndings535
were the reduction of total vessel area in the dalcetrapib arm536
(−4.01mm2 (90% CI: −7.23 to 0.80; p=0.04) and a 7% reduction in537
themost-diseased-carotid segments [96]. A post-hoc analysis of the538
dal-PLAQUE showed that dalcetrapib therapy did not affect vas-539
cular calciﬁcation [101], a marker of the extent of atherosclerosis540
and predictive of CV events and mortality [102].541
Of note, dalcetrapib showed neutral effects also on carotid wall542
imaging in the dal-PLAQUE-2 study (NCT01059682) designed to543
test the hypothesis that dalcetrapib slowed atherosclerosis pro-544
gression inpatientswithevidenceofCHDandcarotid intima-media545
thickness (IMT) ≥0.65mm in the far wall of the common carotids546
[98,103]. No differences were ﬁnally observed in the dal-VESSEL547
trial, where dalcetrapib did not affect NO-dependent endothelial 548
function, BP, or markers of inﬂammation and oxidative stress [97]. 549
The re-evaluation of all of these apparently negative results by 550
using a pharmacogenomic approach has very recently unearthed 551
unexpected ﬁndings, ie, clear interindividual differences in dal- 552
cetrapib responses. Among the 5,543,264 common genetic variants 553
analyzed, a single region with genome-wide signiﬁcance in the 554
dalcetrapib arm of dal-OUTCOMES study, was associated with CV 555
events and identiﬁed in the ADCY9 (adenylate cyclase type 9) gene 556
on chromosome 16, the single genotyped SNP (rs1967309) as the 557
most signiﬁcant. Among the 5749 drug treated patients of the dal- 558
OUTCOMES study, dalcetrapib reduced by 39% the risk of CV events 559
(HR: 0.61; 95% Cl, 0.41–0.92) as well as by 1.0% hs-CRP (p=0.89) 560
in patients bearing the genotype AA at SNP rs1967309 [98, 104]. 561
Signiﬁcant genotype-dependent effects of dalcetrapib were also 562
found in the re-evaluation of dal-PLAQUE-2 study in which regres- 563
sion of cIMT (-0.021±0.083mm, at 12 months) was associated 564
with the AA genotype [98, 105]. The dal-GenE study has thus been 565
planned in order to evaluate the effects of dalcetrapib vs placebo 566
on CV risk in a genetically deﬁned population with a recent CV 567
event and the AA genotype at rs1967309 in the ADCY9. The study 568
is expected to be concluded by August 2020, ie with a time frame 569
of 30 months. Primary end-point will be the time of the ﬁrst event, 570
ie CV death, resuscitated cardiac arrest, non-fatal MI, or non-fatal 571
ischemic stroke (NCT02525939). 572
4.4. Torcetrapib 573
Torcetrapib was the ﬁrst agent in the group of CETP inhibitors 574
and its efﬁcacy on atherosclerosis was evaluated in three clinical 575
studies, ILLUSTRATE (NCT00134173), RADIANCE 1 (NCT00136981) 576
and RADIANCE 2 (NCT00134238), whereas the effect on CV out- 577
comes was evaluated in the ILLUMINATE trial (NCT00134264). For 578
this latter, 15,067 patients were recruited. Despite a 72.1% increase 579
of HDL-C and −24.9% reduction of LDL-C in the torcetrapib arm, 580
there was a signiﬁcant rise in the incidence of primary composite 581
cardiovascular endpoints (HR: 1.25; 95% CI, 1.09–1.44; p=0.001) 582
as well as in all-cause mortality (HR: 1.58; 95% CI, 1.14–2.19; 583
p=0.006) [64]. Due to these untoward ﬁndings, the study was pre- 584
maturely ended. Although this increased mortality was attributed 585
to a slight rise in BP (+5.4mm Hg systolic and +2.0mmHg dias- 586
tolic) [64], prolongation of the QT interval (by +3.3 msec) should be 587
also considered. Indeed, in uncomplicated hypertensive patients, a 588
prolonged ventricular repolarization is a risk factor for IHD and CV 589
mortality [106]. 590
Interestingly, a post hoc exploratory analysis of the ILLUMINATE 591
trial, showed that among the 34 excess deaths in the torcetrapib 592
group, 91% occurred in the 10mg atorvastatin dose subgroup (HR: 593
2.68; 95% CI, 1.58–4.54; p<0.001); the strongest baseline predictor 594
of death was age >70 years (Fig. 3) [107]. 595
In theattempt toexplain the failureof ILLUMINATE trial, another 596
post-hoc analysis showed that torcetrapib signiﬁcantly raised the 597
apoC-III content of HDL-C, a phenomenon elsewhere described as 598
potentially associated to an increased ASCVD risk, ie by stimulating 599
the adhesion of monocytes to endothelial cells and the production 600
of inﬂammatory mediators [108]. Notably, in patients with type 2 601
diabetes, torcetrapib improved glycemic control, as evaluated by a 602
decrement in glucose, insulin levels, HOMA-IR andHb1Ac. All these 603
effects remained apparent up to 12 months [109]. 604
Relative to the vascular imaging studies ILLUSTRATE, RADIANCE 605
1 and 2 on a total of 2000 recruited patients with coronary disease 606
[110], familial hypercholesterolemia [111] or mixed dyslipidemia 607
[112], torcetrapib failed to demonstrate any favorable effect on 608
atheroma volume or atherosclerosis progression, as evaluated by 609
carotid intima media thickness (cIMT) and coronary intravascular 610
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Fig. 3. Estimated Hazard Ratio for all-cause mortality (ACM) by atorvastatin dose (10, 20, 40 and 80mg). T/A, torcetrapib treatment on background atorvastatin; A indicates
atorvastatin background treatment alone. Reproduced with permission of [107].
ultrasound (IVUS). The issue of off target effects has been earlier611
discussed.612
Controversies on torcetrapib effects were also raised by the613
results of animal studies. In New Zealand White rabbits fed a 0.2%614
cholesterol + 10% coconut oil diet leading to a cholesterolemia of615
702mg/dl after 16 weeks [75], torcetrapib treatment raised HDL-C616
>3-fold and prevented the development of atherosclerotic lesions,617
potentiallybyactivating the reverse cholesterol pathway. Sera from618
the torcetrapib-treated rabbits stimulated cholesterol efﬂux to a619
signiﬁcantly greater extent than vs control animals [75]. This report620
indicating a potential stimulation of CE efﬂux by CETP inhibitory621
treatment, did not ﬁnd support in a clinical trial where, contrary to622
expectations, drug treatment failed to raise fecal sterol elimination623
[113].624
5. Different clinical efﬁcacy between evacetrapib and625
anacetrapib: potential explanations626
The different effects of evacetrapib vs those of anacetrapib in627
the ACCELERATE and REVEAL studies, respectively, may be poten-628
tially explained just by the different durations of follow-up [114].629
Indeed, whereas the ACCELERATE trial was prematurely halted630
after2yearsof follow-up, theREVEALstudywascompletedafter4.1631
years. Moreover, ACCELERATE involved less than half the number632
of patients vs REVEAL (12,092 vs 30,449, respectively).633
From the time analysis of the ﬁrst major coronary events per634
year of follow-up in the REVEAL trial, it emerges that the anace-635
trapib protective effect starts after the second year of treatment636
[18]. Interestingly, a similar kinetics of the protective effect has637
been reported after statin treatment, ie a mean 9% reduction in risk638
ofmajor events at 1 year and22%at 2years of follow-up [115]. Thus,639
if the protective activity on major CV events is to be attributed to640
an effect on the lipid proﬁle, similar results should be expected641
with evacetrapib at a similar follow-up; both molecules exert very642
similar lipoprotein changes. The authors of the REVEAL Study, by643
analyzing non-HDL-C data from the statin trials, concluded that644
the lower levels of non-HDL-C (−17mg/dL) found after 4.1 years645
of anacetrapib, should result in a 10% relative decrease in the risk646
of coronary death or MI, a ﬁnding entirely consistent with the 11%647
reduction found in their trial [18].648
The unmet primary endpoints of ACCELERATE trial with evace-649
trapib may possibly be attributed to both on- and off-target effects.650
In the ACCENTUATE study, ie on a combination of evacetrapib with651
atorvastatin, the robust LDL-C reduction (−33.4%) was less pro-652
nounced compared to that of apoB levels (-23%) [116]. Moreover, 653
evacetrapib increased: (i) apoC-III levels, that per se may exert a 654
direct pro-inﬂammatory effect at the arterial wall level by activat- 655
ing vascular cell adhesion molecule-1 and nuclear factor kB, (ii) 656
the HDL apoC-III content, thus impairing HDL functional activity 657
[117] and (iii) both apoE (+28%) [116] and C-reactive protein levels 658
[18], a marker of CV risk [118]. In subjects treated with anace- 659
trapib monotherapy, instead, there were no signiﬁcant changes 660
in the apoE pool size, whereas apoC-III pool size also rose by 76% 661
[119], consequent to a nonsigniﬁcant increase in the apoC-III pro- 662
duction rate and a 35% reduction in the fractional catabolic rate 663
[119]. Further, In the DEFINE study with anacetrapib, there were 664
no signiﬁcant changes in C-reactive protein levels [120]. The poten- 665
tial signiﬁcance of a focal anti-inﬂammatory activity of anacetrapib 666
is supported by the very recently described reduction of in-stent 667
restenosis in rabbits treated with the analog des-ﬂuoro anace- 668
trapib [121], also conﬁrming prior data showing reduced intimal 669
hyperplasia and functional endothelial regenerationwith this agent 670
[121]. 671
Studies on the relative ability of evacetrapib and anacetrapib to 672
promote cholesterol efﬂux from cholesterol loaded macrophages 673
showed that HDL from evacetrapib treated subjects had increased 674
cholesterol efﬂux capacity compared to those on anacetrapib 675
[122,123], a difference ascribable to the evacetrapib capacity to 676
enhance ABCA1-speciﬁc cholesterol efﬂux and pre--HDL for- 677
mation [32]. Anacetrapib treatment did not change pre--HDL 678
formation, while increasing the ABCA1-dependent CE efﬂux into 679
larger HDL2 particles [33, 34,124]. 680
Evacetrapib and anacetrapib further show a different activity 681
on endothelial function. CETP-transgenic mice display a marked 682
increment in HDL-C following evacetrapib treatment, but not an 683
improved endothelial function; this was modestly worsened by 684
anacetrapib [73]. Overall, these last ﬁndings do not support a direct 685
vascular protection by CETP inhibition and are unlikely to explain 686
the different results of the large clinical trials with the two drugs. 687
Relative to the safety proﬁle, evacetrapib raised SBP by 688
1.2mmHg (ACCELERATE trial) vs +0.6mmHg after anacetrapib 689
(REVEAL trial). These off-target effects were similar in magni- 690
tude to those reported for dalcetrapib, but much smaller than the 691
5mm Hg mean rise seen with torcetrapib [64,93,100]. Finally, a 692
major drawback for the clinical use of anacetrapib is the unique 693
pharmacokinetic proﬁle. Data from a small cohort (n =30) of the 694
DEFINE trial have shown detectable concentrations of anacetrapib 695
in plasma2.5–4 years after the last drug dose, associatedwithmod- 696
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Fig. 4. Effect of anacetrapib on coronary death or myocardial infarction. Comparison of the effects of anacetrapib in the REVEAL trial and statins in the Cholesterol Treatment
Trialistsmeta-analysis on coronary death ormyocardial infarction, plotted according to the size of the absolute reduction in non-HDL cholesterol. Reproducedwith permission
[18].
est HDL-C elevations [56]. This ﬁnding is likely consequent to a697
long-termaccumulationof drug in the adipose tissue after one-year698
of treatment [51], as also reported in mice [57]. This was possibly699
a factor in the ﬁnal decision not to continue drug development.700
6. Evidence from Mendelian randomization analyses701
In the effort to study the complexities of lipid biology and702
thus also of CETP inhibition, the genetic procedure of Mendelian703
randomization represents an analog of randomized clinical trials.704
Individuals are randomlyassignedeither to anexposuregroup (car-705
riers of an allele promoting the biological exposure of interest) or706
to a control group (carriers of a different allele). Overall, the basis of707
Mendelian randomization is that if the exposure is causal for a given708
outcome (eg, LDL-C is causally associated with the risk of CHD),709
genetic variants associatedwith exposure should also be associated710
with the outcome [125].711
Byusing aMendelian randomization analysis, Ference et al. gave712
insights on why CETP inhibitors were less effective than expected713
in clinical trials. The Authors concluded that changes in apoB levels714
are better predictors of clinical response to CETP inhibitors plus715
statin vs either LDL-C or HDL-C levels. Thus, the clinical beneﬁt of716
lowering LDL-C depends on how LDL-C lowering is achieved, rather717
thanon the reduction in cholesterol carriedby thoseparticles [126].718
The analysis, comprehensive of 358,205 participants from 77719
studies, aimed at evaluating the causal effects of LDL-C lower-720
ing of CV events due to genetic variants that mimic the effects of721
CETP inhibitors. A speciﬁc genetic score was assigned in order to722
simulate statin-CETP treatment (CETP score≥median and HMGCR723
score≥median) or CETP monotherapy according to a speciﬁc score 724
(CETPscore≥medianandHMGCRscore≤median). The latter geno- 725
type results in a rise ofHDL-C (mean: +4.64mg/dL) and reduction of 726
LDL-C (mean: −2.16mg/dL) and apoB (−1.93mg/dL); it also asso- 727
ciateswith a signiﬁcant lowering of the CHD risk (OR: 0.946; 95%CI, 728
0.921–0.972; p=0.036). Exposure to gene variants that recapitulate 729
statin-CETP treatment led to an attenuation of both apoB reduction 730
(mean: −0.59mg/dL) and CHD risk (OR: 0.985; 95%CI, 0.959-1.012; 731
no longer statistically signiﬁcant). These conclusions were vali- 732
dated in a genome-wide association study in which 21 genetic 733
variants, with naturally occurring discordance between changes in 734
LDL-C and apoB levels, were associated to the risk of CV events; 735
reduction in events was more closely related to the lowering of 736
apoB (OR per 10mg/dL lower apoB: 0.772, 95%CI, 0.701–0.844) 737
vs that of LDL-C (OR per 10mg/dL lower LDL-C: 0.916, 95%CI, 738
0.890–0.943) [127]. 739
Overall, this Mendelian randomization study clearly indicates 740
that apoB is a superior marker of risk of CV events vs LDL, and these 741
ﬁndings are in linewith epidemiological evidence highlighting that 742
apoBmay improve risk assessment of future coronary heart disease 743
events over and beyond LDL-C or non-HDL-C [128–130]. 744
Previous Mendelian randomization studies did not evaluate the 745
combined effect of CETP and HMGGCR variants and did not always 746
report concordant ﬁndings. Niu et al. showed that long-termgenet- 747
ically reduced circulating levels of CETP, due to the CETP rs708272 748
polymorphism,might be causally associatedwith a low risk of CHD. 749
Speciﬁcally, comparing carriers of rs708272-B1B1 genotype or B1 750
allele with carriers of B2B2 genotype, a 0.2g/mL reduction in cir- 751
culating CETP resulted in a 25% (OR: 0.75; 95%CI, 0.10–0.91) and 752
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in a 17% (OR: 0.83; 95%CI, 0.41–0.96) CHD risk reduction, respec-753
tively [131]. Of note, rs708272-B1B1 and B1 allele genotype are754
associated to marginally lower circulating CETP levels compared to755
those observed in B2B2 genotype carriers. These results are in con-756
trastwith others failing to demonstrate a causal relevance between757
increased circulating HDL-C levels and reduced CHD risk in carri-758
ers of the CETP rs708272 [132]. Thompson et al. demonstrated that759
genotypes, associated with moderate inhibition of CETP activity,760
have a weak inverse association with coronary risk [133].761
7. Conclusions762
The results of the REVEAL study have elicited more questions763
than answers relative to the efﬁcacy and suitability of inhibiting764
the CETP enzyme as a new preventive strategy for CV diseases.765
First, it is still unclear whether the CV beneﬁt is related to LDL-C766
lowering or to HDL-C-raising, not leaving out the ancillary proper-767
ties on Lp(a) and non-HDL. The REVEAL data shows a correlation768
between non-HDL-C and CVD risk, in line with the data from the769
CTT meta-analysis (Fig. 4). This observation certainly does not770
exclude the contribution of HDL-C raising to the CV beneﬁt, espe-771
cially because anacetrapib preferentially increases the proportion772
of pro-atherogenic small, lipid-poor LDL particles (LDL subfractions773
4a,4b baseline 9.6% of total LDL vs anacetrapib 26% of total LDL)774
[134,135]. Furthermore, the optimalHDL baseline levels for achiev-775
ing a clinical beneﬁt with anacetrapib still need to be deﬁned, also776
considering the recent results from two prospective population-777
based studies, showing that in the rare cases of extremely elevated778
HDL cholesterol a high all-cause mortality may be detected [136].779
Remarkably, HDL particles found in the high HDL-C induced by780
anacetrapib appear to exhibit physical and functional properties781
of those from healthy normolipidemic subjects [134,137].782
The adverse events observed with anacetrapib seem to be,783
to a certain degree, similar to those reported after the CETP784
inhibitors tested in large phase III clinical RCTs, eg a small rise785
in BP (Table 2). Whether adverse events are a result of an off-786
target effect or directly consequent to CETP inhibition is still a787
matter of debate. Interestingly, an analysis of the 1307 Framingham788
Study participants free of CVD showed that a lower plasma CETP789
activity was associated with a greater increase in pulse pressure,790
possibly because of raised vascular stiffness [138], this latter a sen-791
sitive marker of arterial disease [139]. CETP inhibition, leading to792
enlarged HDL particles, may result in a faulty interaction between793
HDL and the Scavenger Receptor class B type I (SR-BI), a mandatory794
mechanism for the activation of endothelial nitric oxide synthase795
[140].796
In conclusion, the possible therapeutic window for anacetrapib797
in dyslipidemic patients with CHD could be envisioned in a more798
personalized therapy for selected patients with low HDL-C at high799
CV risk or low HDL-C patients intolerant to statins in whom LDL-C800
would typically be >100mg/dL. The combination with other lipid801
lowering therapies, ie ezetimibe, could also be considered. Unfor-802
tunately, Merck already announced that it will not seek regulatory803
approval for anacetrapib, since its clinical proﬁle does not support804
regulatory ﬁlings. With this waiver, dalcetrapib (Dal-GenE study)805
andCKD-519 (NCT02977065) remain the twomoleculeswithin this806
area still in clinical development.807
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